

glac Biotech Co., Ltd.

100% NATURAL

GMO FREE

GLUTEN FREE

MP108

Lactobacillus rhamnosus

GRAS GENERALLY RECOGNIZED AS SAFE

CHINESE INFANT & TODDLER FOOD

FINALIST NUTRA INGREDIENTS ASIA AWARDS 2021

MARKET INSIGHT

According to the World Allergy Organization, allergies affect over 30% of the global population, with 80% of families being affected.

Health Solution: Immune Support for both Infant, Children & Adult with Top Safety Recognitions

- High-quality probiotic strain tailored to enhance the immune system, suitable for children aged 4-48 months with skin concerns and adults dealing with seasonal respiratory issues【Wu *et al*., 2017】,【Ried *et al*., 2022】
- SCI Papers:

• Ried, K., *et al*. (2022). Effects of a probiotic formulation on seasonal allergic rhinitis in adults—a randomized double-blind placebo-controlled trial: the probiotics for hay fever trial. *Frontiers in nutrition, 9,* 887978.
• Zhang, B., *et al*. (2021). *Lactobacillus rhamnosus* MP108: Toxicological evaluation. *Journal of Food Science, 86*(1), 228-241.
• Wu, Y. J., *et al*. (2017). Evaluation of efficacy and safety of *Lactobacillus rhamnosus* in children aged 4–48 months with atopic dermatitis: An 8-week, double-blind, randomized, placebo-controlled study. *Journal of microbiology, immunology and infection, 50*(5), 684-692.

Strain Information

- Specification of ingredient : $3x10^{11}$ CFU/g
- Daily dosage: 5×10^{9} CFU
- Storage: < 4°C, away from sunlight and moisture.
- Shelf life : 3 years


Dosage form

CAPSULES STICKS/SACHETS DROPS


PROBIOTICS GLAC BIOTECH

Clinical Study 【Wu *et al*., 2017】(Two-center, Double-blind, Randomized, Placebo-controlled)
66 infants aged 4-48 months with atopic dermatitis (AD) participated in the trial. The study demonstrated that after taking 5 billion CFU/day for 8 weeks, there was evidence of immune support.

01 The Average Improvement Score of AD (Per-Protocol) at 2nd, 4th, and 6th Weeks




02 The Average Improvement Score of AD at 8th Week (Per-Protocol) (Intent to Treat)




Clinical Study 【Ried *et al*., 2022】(Randomized, Double-blind, Placebo-controlled)
40 adults completed the 10–12-week intervention, the active group showed significant symptom reduction compared to the placebo group, particularly in runny nose (p = 0.04), itchy eyes (p = 0.01) and less irritability (p = 0.007). Immunological parameters, like the T-helper cell ratio (Th1/Th2), improved significantly in the active group compared to the placebo group. Most microbial changes showed no statistically significant differences between the groups.

01 Nasal &Eye Symptom Scores (Subgroup n=40)



02 Total Nasal & Eye Symptoms Scores(n=40)



Total nasal and eye symptom scores at baseline (yellow/orange bars) and 12 weeks (blue bars) of participants who took the full course of 10–12 week trial intervention (n = 40).
(A) Individual symptom scores and (B) total nasal and/or eye symptom scores. Higher scores represent more severe symptoms.

glac Biotech Co., Ltd.

Expert In Probiotics and Postbiotics Integrated Solution

Email globalsales@glac.com.tw

Taipei office 7F, 3-2 Yuanqu St., Nangang Dist., Taipei 115, Taiwan (R.O.C.)

Website LinkedIn